103 results on '"Rueter, Jens"'
Search Results
2. Health care utilization and behavior changes after workplace genetic testing at a large US health care system
3. Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer
4. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
5. Epistemic Beliefs: Relationship to Future Expectancies and Quality of Life in Cancer Patients
6. Utilization of genomic tumor testing (GTT) among community oncologists participating in SWOG S2108CD.
7. Socioeconomic and urban-rural disparities in genome-matched treatment receipt and survival after genomic tumor testing.
8. The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State
9. Urban-Rural and Socioeconomic Differences in Patient Knowledge and Perceptions of Genomic Tumor Testing
10. Differences in cancer patients’ and clinicians’ preferences for disclosure of uncertain genomic tumor testing results
11. Molecular profiling of gynecologic cancers for treatment and management of disease – demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants
12. Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
13. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
14. Sociodemographic differences in treatment and survival for patients who receive genomic tumor testing in a rural state.
15. Patientsʼ Expectations of Benefits From Large-Panel Genomic Tumor Testing in Rural Community Oncology Practices
16. Die institutionelle Organisation der Armut. Historische Differenzlinien zwischen Fürsorge und Sozialtechnologie
17. Einleitung
18. Feasibility and Value of Genomic-Profiling in Cancer of Unknown Primary: Real-World Evidence from Prospective Profiling Study
19. Advancing Genomic Cancer Medicine in Rural and Underserved States.
20. Regulatory T Cells: A New Frontier in Cancer Immunotherapy
21. CD26-/DPP IV-Positive Lymphocytes in Murine Acute Experimental Colitis
22. Inhibition of Dipeptidylpeptidase IV (DPP IV, CD26) Activity Modulates Surface Expression of CTLA-4 in Stress-Induced Abortions
23. 307 Patients expectations of benefits from large-panel genomic tumor testing in rural community oncology practices
24. Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer
25. Molecular profiling of CNS tumors for the treatment and management of disease
26. Maine Cancer Genomics Initiative: A Model for Translational Outreach
27. Clinical Utility of Molecular Profiling in Recurrent Glioblastoma Multiforme
28. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence
29. BIOM-23. MOLECULAR PROFILING IDENTIFIES NOVEL BIOMARKERS IN A RURAL COHORT OF PATIENTS WITH GLIOBLASTOMA
30. The influence of uncertainty and uncertainty tolerance on attitudes and self-efficacy about genomic tumor testing
31. Prospective study for comprehensive genomic profiling (GP) in cancer of unknown primary (CUP): Feasibility, molecular landscape, and clinical utility in current era.
32. Prediction of Tissue of Origin and Molecular Subtypes for Cancer of Unknown Primary Using Machine Learning
33. Community oncologists' perceptions and utilization of large-panel genomic tumor testing.
34. The influence of uncertainty and uncertainty tolerance on attitudes and self-efficacy about genomic tumor testing.
35. A donor-dependent in vivo model for single agent and drug combination cytokine release syndrome safety evaluation.
36. Utilizing data from patient-derived xenograft mouse models of human tumors to inform clinical decision making in Molecular Tumor Boards (MTB) deliberations.
37. Genomic Profiling of Two Histologically Distinct Rare Urothelial Cancers in a Clinical Setting to Identify Potential Therapeutic Options for Treatment and Management of Disease
38. Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib
39. Abstract 2033: Testing the combined effects of low dose olaparib plus ibrutinib on MCL cytotoxicity
40. Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy
41. TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
42. Health care utilization and behavior changes after workplace genetic testing at a large US health care system
43. TMOD-39. A NOVEL EX VIVO TUMOR SLICE CULTURE SYSTEM AS A TOOL FOR BASIC AND CLINICAL RESEARCH
44. Abstract 649: Biobank collaboration enables cancer modeling with high quality biospecimens and data
45. A Novel Automated Analysis Of Flow Cytometry Data Identifies Distinct Cell Signatures In The Immune System Of CLL Patients
46. Widerstand an allen Fronten! Plädoyer für eine selbstbestimmtere, politische und kritische Soziale Arbeit
47. Mechanismen psychosozialer DeKonstruktion im globalen Kapitalismus
48. Die Anatomie der Gesellschaft
49. Abstract Author Index.
50. Abstract Author Index.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.